The American Journal of Medicine
Volume 121, Issue 3 , Pages 219-225 , March 2008

C-Reactive Protein Is an Independent Predictor of Severity in Community-acquired Pneumonia

  • James D. Chalmers, MBChB, MRCP (UK)

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to James Chalmers, MBChB, MRCP (UK), Department of Respiratory Medicine, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA, United Kingdom.
    • ,
  • Aran Singanayagam, MBChB
    • ,
  • Adam T. Hill, MD, FRCPE

References 

  1. Niederman MS, McCombs JI, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther. 1998;20:820–837
  2. Neill AM, Martin IR, Weir R, et al. Community-acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax. 1996;51:1010–1016
  3. Lim WS, Van Der Eerden M, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–382
  4. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243–250
  5. Smith RP, Lipworth BJ, Cree IA, et al. C-reactive protein (A clinical marker in community-acquired pneumonia). Chest. 1995;108(5):1288–1291
  6. Garcia Vazquez E, Martinez JA, Mensa J, et al. C-reactive protein levels in community-acquired pneumonia. Eur Respir J. 2003;21(4):702–705
  7. British Thoracic Society. Guidelines for the Management of Community Acquired Pneumonia in Adults—2004 Update. London, UK: British Thoracic Society; 2004;
  8. Hansson LO, Hedlund JU, Ortqvist AB. Sequential changes of inflammatory and nutritional markers in patients with community-acquired pneumonia. Scand J Clin Lab Invest. 1997;57:111–118
  9. Martin C, Saux P, Mege JL, et al. Prognostic values of serum cytokines in septic shock. Intensive Care Med. 1994;20:272–277
  10. Hedlund J. Community-acquired pneumonia requiring hospitalisation (Factors of importance for the short- and long-term prognosis). Scand J Infect Dis Suppl. 1995;97:1–60
  11. Lobo SM, Lobo FR, Bota DP, et al. C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest. 2003;123:2043–2049
  12. Castell JV, Gomez-Lechon MJ, David M, et al. Acute phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12:1179–1186
  13. Moussa K, Michie HJ, Cree IA, et al. Phagocyte function and cytokine production in community acquired pneumonia. Thorax. 1994;49(2):107–111
  14. Marik P, Kraus P, Sribante J, et al. Hydrocortisone and tumor necrosis factor in severe community acquired pneumonia (A randomised controlled study). Chest. 1993;104(2):389–392
  15. Atunes G, Evans SA, Lordan JL, Frew AJ. Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. Eur Respir J. 2002;20(4):990–995
  16. Glynn P, Coakley R, Kilgallen I, et al. Circulating interleukin 6 and interleukin 10 in community acquired pneumonia. Thorax. 1999;54(1):51–55
  17. Puren J, Feldman C, Savage N, et al. Patterns of cytokine expression in community acquired pneumonia. Chest. 1995;107:1342–1349
  18. Admirall J, Bolibar I, Toran P, et al. Contribution of c-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest. 2004;125(4):1192–1195
  19. Seppa Y, Bloigu A, Honkanen PO, et al. Severity assessment of lower respiratory tract infection in elderly patients in primary care. Arch Intern Med. 2001;161:2709–2713
  20. Buising KL, Thursky KA, Black JF, et al. A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax. 2006;61:419–424

PII: S0002-9343(07)01180-1

doi: 10.1016/j.amjmed.2007.10.033

The American Journal of Medicine
Volume 121, Issue 3 , Pages 219-225 , March 2008

Article Tools